Tailoring of immunosuppressive drug therapy to the specific requirements of the individual
patient to optimize efficacy and minimize toxicity remains one of the biggest challenges in …

The immunosuppressive drugs used in solid-organ transplantation are potent and toxic
agents with narrow therapeutic ranges. Underdosing is associated with immunological …

The immunosuppressive drugs used in organ transplantation typically have a narrow
therapeutic index, with wide variation in the blood concentration achieved from a given dose …

Interindividual variability in immunosuppressive drug responses might be partly explained
by genetic variants in proteins involved in the immune response or associated with IS …

The transplantation literature includes numerous papers that report associations between
polymorphisms in genes encoding metabolizing enzymes and drug transporters, and …

Existing immunosuppressive therapies used for solid-organ transplantation have narrow
therapeutic indices, whereby underdosing is associated with acute immunological rejection …

Advances in the management of patients after solid organ transplantation have led to
dramatic decreases in rates of acute rejection, but long-term graft and patient survival have …

With the advent of new immunosuppressants and formulations, the elucidation of molecular
targets and the evolution of therapeutic drug monitoring, the field of organ transplantation …

Organ transplantation has become an important additional option for patients with organ
failure. Immunosuppressive drugs showing a very narrow therapeutic window have to be …

The promising role of pharmacogenetics in the attempt to elucidate the inherited basis of
differences between individual responses to drugs lies in its potential ability to identify the …